Uplizna market report points to stronger demand for oral MS therapies

Nov. 19, 2026
Uplizna market report points to stronger demand for oral MS therapies
By AI, Created 14:00 UTC, Nov 19, 2026, AGP -

The Business Research Company says the Uplizna market is set to grow through 2035 as multiple sclerosis diagnoses rise and demand increases for convenient oral treatments. North America led the market in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Why it matters: - The Uplizna market is tied to a growing global need for multiple sclerosis treatments, especially therapies that are easier for patients to take long term. - Rising demand for early intervention, relapse prevention and adherence support is shaping how MS drugs are evaluated in the market. - The report points to a broader shift toward targeted neuroimmunology therapies and personalized treatment plans.

What happened: - The Business Research Company released a global market report on Uplizna covering market size, trends and forecasts for 2026-2035. - The report says historical growth came from higher MS diagnosis rates, neurologist-led treatment protocols, broader access to disease-modifying therapies, patient education efforts and clinical support for sphingosine receptor modulators. - The report says future growth will be driven by demand for convenient oral therapies, stronger early intervention efforts, personalized MS treatment plans, more neuroimmunology investment and longer-term efficacy studies. - The report highlights trends including wider acceptance of oral immunomodulatory drugs, greater demand for long-term MS management medicines, expansion of targeted immune modulation therapies, stronger adherence strategies and better relapse prevention. - A free sample of the report is available here.

The details: - Uplizna, also known as ozanimod, is an oral drug approved for relapsing forms of multiple sclerosis. - The drug modulates sphingosine 1-phosphate receptors, which limits immune-cell movement into the central nervous system. - Clinical evidence shows Uplizna can reduce relapse frequency and slow disability progression. - The report links market growth to the rising worldwide prevalence of multiple sclerosis. - MS is a chronic autoimmune disease affecting the central nervous system and causing neurological symptoms. - The report cites better diagnostics, growing awareness, aging populations and genetic factors as contributors to higher prevalence. - NHS England said in July 2024 that MS affects more than 150,000 people in the UK and more than 120,000 in England, with higher prevalence among women. - The full report is available here. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market-hotspot infographics, key-technology analysis and updated graphics and tables.

Between the lines: - North America’s 2025 lead suggests the market remains strongest where MS diagnosis rates and healthcare infrastructure are already mature. - Asia-Pacific’s projected faster growth points to expanding access and awareness rather than a current market leadership position. - The emphasis on adherence and relapse prevention shows that market demand is shifting toward therapies that support chronic disease management, not just acute symptom control.

What's next: - The report expects more investment in neuroimmunology research and more long-term efficacy data to influence prescribing and market growth. - Wider adoption of oral immunomodulatory drugs and targeted immune modulation therapies could reshape competition in MS treatment. - Market performance will likely depend on how quickly healthcare systems expand diagnosis, access and early-treatment pathways.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Middle East News Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Middle East News Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.